Cargando…

Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study

BACKGROUND: Immune checkpoint inhibitors (ICIs) provided a paradigm shift for advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical prognosis of such patients. Pembrolizumab is a humanized anti-programmed death cell protein 1 (PD-1) monoclonal antibody, approved for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Tianxing, Ding, Yun, Chen, Long, Zhu, Lihuan, Lin, Jinlan, Zhang, Jiguang, Huang, Yangyun, Li, Wujin, Lin, Rongjia, Pan, Xiaojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867846/
https://www.ncbi.nlm.nih.gov/pubmed/33569208
http://dx.doi.org/10.21037/jtd-20-3413
_version_ 1783648356489232384
author Guo, Tianxing
Ding, Yun
Chen, Long
Zhu, Lihuan
Lin, Jinlan
Zhang, Jiguang
Huang, Yangyun
Li, Wujin
Lin, Rongjia
Pan, Xiaojie
author_facet Guo, Tianxing
Ding, Yun
Chen, Long
Zhu, Lihuan
Lin, Jinlan
Zhang, Jiguang
Huang, Yangyun
Li, Wujin
Lin, Rongjia
Pan, Xiaojie
author_sort Guo, Tianxing
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors (ICIs) provided a paradigm shift for advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical prognosis of such patients. Pembrolizumab is a humanized anti-programmed death cell protein 1 (PD-1) monoclonal antibody, approved for the treatment of patients with advanced or metastatic NSCLC. This article investigated and reported on the efficacy and safety of pembrolizumab in the treatment of advanced NSCLC in our center since 2019. METHODS: Patients with clinical stage III–IV NSCLC treated with pembrolizumab for ≥4 cycles were enrolled as participants in this study. Pembrolizumab was administered intravenously at a dose of 2 mg/kg every 3 weeks. A cycle was defined as 3 weeks of treatment. We assessed the efficacy and safety of pembrolizumab through the collection of researcher-assessed tumor response, survival, and safety data. RESULTS: A total of 24 patients were included in this study. The median follow-up time was 9 months (3–20 months) and the median period of pembrolizumab therapy was 7 cycles (4–21 cycles). The objective response rate (ORR) was 45.8% and disease control rate (DCR) was 70.8%. The median overall survival (OS) and progression-free survival (PFS) times were not reached. A total of 2 programmed death-ligand 1 (PD-L1)-negative participants were treated with pembrolizumab combined with chemotherapy and there was no significant progression during the follow-up period. During the follow-up period, 8 patients underwent surgery. The major pathological response (MPR) was 75% and pathological complete response (pCR) was 50%. A case that was preoperatively diagnosed with clinical stage IV achieved pCR after 6 cycles of pembrolizumab combined with chemotherapy. The incidence of adverse effects (AEs) was 83.3%, and 16.7% of these were serious AEs (grade ≥3), which was similar to the incidence reported in previous studies. CONCLUSIONS: This real-world data supports the use of pembrolizumab for advanced NSCLC, including those cases that are PD-L1 negative. More importantly, pembrolizumab immunotherapy can also provide the potential of local treatment for patients with advanced NSCLC, which has wide application prospects in the field of surgery.
format Online
Article
Text
id pubmed-7867846
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78678462021-02-09 Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study Guo, Tianxing Ding, Yun Chen, Long Zhu, Lihuan Lin, Jinlan Zhang, Jiguang Huang, Yangyun Li, Wujin Lin, Rongjia Pan, Xiaojie J Thorac Dis Original Article BACKGROUND: Immune checkpoint inhibitors (ICIs) provided a paradigm shift for advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical prognosis of such patients. Pembrolizumab is a humanized anti-programmed death cell protein 1 (PD-1) monoclonal antibody, approved for the treatment of patients with advanced or metastatic NSCLC. This article investigated and reported on the efficacy and safety of pembrolizumab in the treatment of advanced NSCLC in our center since 2019. METHODS: Patients with clinical stage III–IV NSCLC treated with pembrolizumab for ≥4 cycles were enrolled as participants in this study. Pembrolizumab was administered intravenously at a dose of 2 mg/kg every 3 weeks. A cycle was defined as 3 weeks of treatment. We assessed the efficacy and safety of pembrolizumab through the collection of researcher-assessed tumor response, survival, and safety data. RESULTS: A total of 24 patients were included in this study. The median follow-up time was 9 months (3–20 months) and the median period of pembrolizumab therapy was 7 cycles (4–21 cycles). The objective response rate (ORR) was 45.8% and disease control rate (DCR) was 70.8%. The median overall survival (OS) and progression-free survival (PFS) times were not reached. A total of 2 programmed death-ligand 1 (PD-L1)-negative participants were treated with pembrolizumab combined with chemotherapy and there was no significant progression during the follow-up period. During the follow-up period, 8 patients underwent surgery. The major pathological response (MPR) was 75% and pathological complete response (pCR) was 50%. A case that was preoperatively diagnosed with clinical stage IV achieved pCR after 6 cycles of pembrolizumab combined with chemotherapy. The incidence of adverse effects (AEs) was 83.3%, and 16.7% of these were serious AEs (grade ≥3), which was similar to the incidence reported in previous studies. CONCLUSIONS: This real-world data supports the use of pembrolizumab for advanced NSCLC, including those cases that are PD-L1 negative. More importantly, pembrolizumab immunotherapy can also provide the potential of local treatment for patients with advanced NSCLC, which has wide application prospects in the field of surgery. AME Publishing Company 2021-01 /pmc/articles/PMC7867846/ /pubmed/33569208 http://dx.doi.org/10.21037/jtd-20-3413 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Guo, Tianxing
Ding, Yun
Chen, Long
Zhu, Lihuan
Lin, Jinlan
Zhang, Jiguang
Huang, Yangyun
Li, Wujin
Lin, Rongjia
Pan, Xiaojie
Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
title Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
title_full Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
title_fullStr Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
title_full_unstemmed Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
title_short Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
title_sort evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867846/
https://www.ncbi.nlm.nih.gov/pubmed/33569208
http://dx.doi.org/10.21037/jtd-20-3413
work_keys_str_mv AT guotianxing evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT dingyun evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT chenlong evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT zhulihuan evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT linjinlan evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT zhangjiguang evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT huangyangyun evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT liwujin evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT linrongjia evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy
AT panxiaojie evaluationofpembrolizumabforthetreatmentofadvancednonsmallcelllungcanceraretrospectivesinglecentresinglearmstudy